Printer Friendly

Study Finds Significant Tissue Modification Associated with Orbital Atherectomy Led to Better Stent Apposition, Expansion.

M2 PHARMA-May 19, 2015-Study Finds Significant Tissue Modification Associated with Orbital Atherectomy Led to Better Stent Apposition, Expansion


A new article e-published in May 2015 in The Journal of Catheterization and Cardiovascular Intervention highlights the mechanical effect of orbital atherectomy and rotational atherectomy in treating heavily calcified coronary lesions, US-based medical device maker Cardiovascular Systems, Inc. (NASDAQ: CSII) said on Tuesday.

The article, titled "Optical Coherence Tomography Assessment of the Mechanistic Effects of Rotational and Orbital Atherectomy in Severely Calcified Coronary Lesions," details results from a study led by Dr. Annapoorna Kini, Professor of Cardiology at the Mount Sinai Hospital and Icahn School of Medicine, and director of The Cardiac Catheterization Lab at Mount Sinai Hospital.

Kini's study sought to assess the mechanical effects of RA and OA on heavily calcified coronary lesions and subsequent stent placement using optical coherence tomography, an established medical imaging technique that uses light to capture three-dimensional images from within arteries and other biological tissue.

The retrospective analysis included 20 consecutive patients who were treated with either RA or OA.

While small case reports have described the mechanistic effect of RA in calcified coronary lesions, there has been no imaging study to assess the effect of OA on coronary artery architecture and/or compare the effects of two atherectomy devices.

CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow.

Cardiovascular Systems is focused on developing and commercialising innovative solutions for treating vascular and coronary disease.

The company's Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 19, 2015
Previous Article:GI Dynamics Presents Study Results Comparing Gastric Bypass and EndoBarrier Therapy.
Next Article:US FDA grants approval to Corbus Pharmaceuticals' Phase II trial with Resunab.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |